| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 09 Oct 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 15 Jul 2026 | SCHEDULE 13G/A |
| 02 Jul 2026 |
Form 4: Toledano Miranda Jayne, Director
Received 50,000 shares as a grant or award |
| 02 Jul 2026 |
Form 4: Smith Justin Adam, Director
Received 50,000 shares as a grant or award |
| 02 Jul 2026 |
Form 4: Herskowitz Neil, Director
Received 50,000 shares as a grant or award |
| 29 Jun 2026 |
Form 4: Toledano Miranda Jayne, Director
Received 10,000 shares as a grant or award |
| 26 Jun 2026 |
Form 4: Smith Justin Adam, Director
Received 10,000 shares as a grant or award |
| 26 Jun 2026 |
Form 4: Herskowitz Neil, Director
Received 10,000 shares as a grant or award |
| 26 Jun 2026 |
Form 4: Pearce Michael Cooper, Director
Received 10,000 shares as a grant or award |
| 26 Jun 2026 |
Form 4: Rosenwald Lindsay A Md, Director
Received 10,000 shares as a grant or award |
| 26 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Journey Medical Corporation (the “Company”) held its 2026 Annual Meeting at 11:00 a.m. Eastern Time by means of an online virtual meeting platform. Stockholders representing 16,145,526 shares of common stock, par value ... |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million |
| 30 Apr 2026 | DEFA14A |
| 30 Apr 2026 | Proxy statement: annual meeting |
Loading...